{"TopicDetails": {"type": 0, "ccm2Id": 31077472, "cftId": 0, "identifier": "IMI2-2016-09-01", "title": "ADDRESSING THE CLINICAL BURDEN OF CLOSTRIDIUM DIFFICILE INFECTION (CDI): EVALUATION OF THE BURDEN, CURRENT PRACTICES AND SET-UP OF A EUROPEAN RESEARCH PLATFORM  (PART OF THE IMI NEW DRUGS FOR BAD BUGS (ND4BB) PROGRAMME)", "publicationDateLong": 1461715200000, "callIdentifier": "H2020-JTI-IMI2-2016-09-two-stage", "callTitle": "H2020-JTI-IMI2-2016-09-two-stage", "callccm2Id": 31077473, "allowPartnerSearch": true, "workProgrammepart": {"id": 3051, "ccm_id": 31078048, "wp_part": "H2020-JTI-IMI-2016", "wp_year": "H2020-JTI-IMI-2016", "wp_title": "IMI2 Work Plan 2016", "wp_website": "http://www.imi.europa.eu/", "wp_document": "http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp16-imi_en.pdf"}, "frameworkProgramme": {"id": 31045243, "abbreviation": "H2020", "description": "Horizon 2020 Framework Programme"}, "programmeDivision": [{"id": 31047894, "abbreviation": "EU.3.1.", "description": "Health, demographic change and wellbeing"}, {"id": 31047893, "abbreviation": "EU.3.", "description": "Societal Challenges"}, {"id": 31062059, "abbreviation": "EU.3.1.7.", "description": "Innovative Medicines Initiative 2 (IMI2)"}, {"id": 31045244, "abbreviation": "EC", "description": "EC Treaty"}, {"id": 31062060, "abbreviation": "EU.3.1.7.1.", "description": "Antimicrobial resistance"}], "topicMGAs": [], "tags": ["Public Health and Epidemiology", "infectious diseases", "pathogens agents", "bacteria", "gram-positives", "antimicrobial resistance"], "keywords": ["Bacteria", "Public health and epidemiology", "Gram-positive"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "IMI2-RIA Research and Innovation action", "typeOfMGA": []}], "plannedOpeningDate": "27 April 2016", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["26 July 2016", "10 January 2017"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3202715": [{"action": "IMI2-2016-09-03 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "27 April 2016", "deadlineModel": "two-stage", "deadlineDates": ["26 July 2016", "10 January 2017"], "budgetYearMap": {"2016": 117656000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2016-09-02 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "27 April 2016", "deadlineModel": "two-stage", "deadlineDates": ["26 July 2016", "10 January 2017"], "budgetYearMap": {"2016": 117656000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2016-09-01 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "27 April 2016", "deadlineModel": "two-stage", "deadlineDates": ["26 July 2016", "10 January 2017"], "budgetYearMap": {"2016": 117656000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2016-09-04 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "27 April 2016", "deadlineModel": "two-stage", "deadlineDates": ["26 July 2016", "10 January 2017"], "budgetYearMap": {"2016": 117656000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2016-09-06 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "27 April 2016", "deadlineModel": "two-stage", "deadlineDates": ["26 July 2016", "10 January 2017"], "budgetYearMap": {"2016": 117656000}, "budgetTopicActionMap": {}}, {"action": "IMI2-2016-09-05 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "27 April 2016", "deadlineModel": "two-stage", "deadlineDates": ["26 July 2016", "10 January 2017"], "budgetYearMap": {"2016": 117656000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2016"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p>Infection with <em>Clostridium difficile</em>, a Gram-positive spore-forming anaerobe, is the most common cause of nosocomial diarrhoea in developed countries and leads to symptoms that range from self-limiting mild-moderate watery diarrhea to severe fulminant diarrhea, abdominal pain and pseudomembranous colitis. In some patients it may progress to toxic megacolon, colonic perforation and death.</p><p>Over 500,000 new cases of <em>C. difficile</em> infection occur each year in the US and estimates suggest greater than 400,000 diagnosed CDI events occur annually in Europe, although the true incidence is likely to be much higher. Furthermore, the burden of CDI outside of the acute care hospital environment, particularly in nursing homes and long-term care facilities, is under-estimated.</p><p>There is therefore a need to develop a robust assessment of the burden of CDI and current practices in Europe. </p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>Development of a detailed understanding of the epidemiology and clinical impact of CDI; more specifically to:</p><ul level=\"0\">  <li>align and understand the unmet public health needs relating to CDI;</li>  <li>identify the direct and long term burden on healthcare systems;</li>  <li>set up a EU research platform that will provide support for potential proof of concept studies of new prevention and treatment strategies.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p>These efforts can be expected to result in the support of adequate public health intervention and practices. It will help in speeding up the development of alternative prevention and treatment approaches.</p>\n", "conditions": "<p>Please read carefully all provisions below before the preparation of your application !</p>\r\n<p>You can access the description of the&nbsp;different topics in the <a target=\"_blank\" href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche16-9-imi2-ju_en.pdf\">IMI2&nbsp;Call 9 topics text&nbsp;</a></p>\r\n<p>The budget breakdown for this Call is given at the end&nbsp;of the Call topics text, in the <a target=\"_blank\" href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche16-9-imi2-ju_en.pdf\">Call Conditions </a>section (starting page 61), as well as the following information :</p>\r\n<ol>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">List of countries and applicable rules for funding</span></strong><br />\r\n    &nbsp;</li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Eligibility and admissibility conditions<br />\r\n    </span></strong></li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Evaluation criteria and procedure, scoring and threshold:</span></strong> described in&nbsp;the <a target=\"_blank\" href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.3_en.pdf\">Manual for submission, evaluation and grant award</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />\r\n    &nbsp;</li>\r\n    <li><span style=\"color: rgb(0,51,102)\"><strong>Indicative timetable for evaluation and grant agreement<br />\r\n    </strong></span></li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Provisions, proposal templates and evaluation forms for the type of action under this topic:</span></strong> <br />\r\n    <br />\r\n    <strong><u>IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):</u><br />\r\n    </strong><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-rel-prov-imi-ju_en.pdf\">Summary of the most relevant provisions for participating in IMI2 actions</a><br />\r\n    <a target=\"_blank\" href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/ef/h2020-call-ef-imi2-ria-ia-2016_en.pdf\">Standard evaluation form</a><br />\r\n    Proposal templates are available after entering the submission tool SOFIA.<br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-mga-imi_en.pdf\">IMI2 Model Grant Agreement</a><br />\r\n    <a target=\"_blank\" href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/legal/templ/h2020_tmpl-clinical-studies-imi-ju_en.pdf\">Template for Essential Clinical Trials Information</a><br />\r\n    <br />\r\n    <br />\r\n    &nbsp;</li>\r\n</ol>", "supportInfo": "<p><strong><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/index_en.htm\">H2020 Online Manual</a></strong> your online guide on the procedures from proposal submission to managing your grant.<br />\r\n<br />\r\n&nbsp;</p>\r\n<p><strong><span>Contact the IMI&nbsp;JU&nbsp;Programme Office : <a href=\"mailto:Infodesk@imi.europa.eu\">Infodesk@imi.europa.eu</a> Tel : 0032 (2) 221 81 81</span></strong></p>\r\n<p><strong><span>Contact the IMI&nbsp;SOFIA&nbsp;Helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc. : <a href=\"mailto:sofia@imi.europa.eu\">sofia@imi.europa.eu</a> </span></strong></p>\r\n<p><strong><span><a href=\"http://ec.europa.eu/research/participants/portal/desktop/en/support/faq.html\">Participant Portal FAQ</a> </span></strong><span>&ndash; Submission of proposals.</span><br />\r\n<strong><br />\r\n<span><a href=\"http://ec.europa.eu/research/participants/portal4/desktop/en/support/national_contact_points.html\">National Contact Points (NCP)</a>&nbsp;-&nbsp;</span></strong><span>contact your NCP for further assistance.</span><br />\r\n<strong><br />\r\n<span><a href=\"http://ec.europa.eu/research/index.cfm?lg=en&amp;pg=enquiries\">Research Enquiry Service</a></span></strong><span> &ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span><br />\r\n<a href=\"http://een.ec.europa.eu/\"><br />\r\n<strong>Enterprise Europe Network</strong></a> &ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.</p>\r\n<p>Contact the EIT for further assistance related to the call, topics and the content of proposals via the <strong><a href=\"http://eit.europa.eu/interact/contact-us\">Contact Page on the EIT website</a></strong>.<br />\r\n<a href=\"http://www.imi.europa.eu/content/states-representatives-groups\"><br />\r\n<strong>IMI States Representative Group (SRG)</strong></a> &ndash; contact you SRG member for assistance.<br />\r\n<strong><br />\r\nEthics</strong> &ndash; for compliance with ethical issues, see the<a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm\"> Participant Portal</a>&nbsp;and&nbsp;<a href=\"http://ec.europa.eu/research/swafs/index.cfm?pg=policy&amp;lib=ethics\">Science and Society Portal</a><br />\r\n<a href=\"http://www.iprhelpdesk.eu/\"><br />\r\n<strong>European IPR Helpdesk</strong></a> assists you on intellectual property issues<br />\r\n<a href=\"http://www.cen.eu/cen/Services/Innovation/Pages/default.aspx\"><br />\r\n<strong>CEN</strong></a> and <a href=\"http://www.cenelec.eu/aboutcenelec/whatwestandfor/fosterinnovation/randd.html\"><strong>CENELEC</strong></a>, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at <a href=\"mailto:research@cencenelec.eu\">research@cencenelec.eu</a>.<br />\r\n<a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\"><br />\r\n<strong>The European Charter for Researchers and the Code of Conduct for their recruitment</strong></a><br />\r\n<a href=\"http://www.imi.europa.eu/content/partner-search\"><br />\r\n<strong>IMI Partner Search Tool</strong></a> helps you find a partner organisation for your proposal</p>", "sepTemplate": "<p>To access the Electronic Submission Service of the topic, please select the <strong>type of action</strong> that is most relevant to your proposal from the list below and click on the <strong>'Start Submission' </strong>button. You will then be asked to confirm your choice of the type of action and topic, as these cannot be changed in the submission system. Upon confirmation you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.</p>", "links": [{"callIdentifier": "H2020-JTI-IMI2-2016-09-two-stage", "status": "Closed", "criterionType": "SubFundingScheme", "criterionTypeDescription": "subfunding schemes", "criterionCode": "IMI2-RIA", "criterionDescription": "Research and Innovation action", "url": "https://sofia.imi.europa.eu/Pages/Default.aspx", "startDate": "Apr 26, 2016 5:00:00 PM"}], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Apr 27, 2016 6:30:00 PM", "lastChangeDate": "Apr 27, 2016 6:30:00 PM", "content": "The submission session is now available for: IMI2-2016-09-01(IMI2-RIA), IMI2-2016-09-03(IMI2-RIA), IMI2-2016-09-02(IMI2-RIA), IMI2-2016-09-04(IMI2-RIA), IMI2-2016-09-06(IMI2-RIA), IMI2-2016-09-05(IMI2-RIA)"}, {"approvalDate": "Apr 27, 2016 5:56:45 PM", "lastChangeDate": "Apr 27, 2016 5:56:45 PM", "content": "The submission session is now available for: IMI2-2016-09-01(IMI2-RIA), IMI2-2016-09-03(IMI2-RIA), IMI2-2016-09-02(IMI2-RIA), IMI2-2016-09-04(IMI2-RIA), IMI2-2016-09-06(IMI2-RIA), IMI2-2016-09-05(IMI2-RIA)"}, {"approvalDate": "Apr 27, 2016 5:40:50 PM", "lastChangeDate": "Apr 27, 2016 5:40:50 PM", "content": "The submission session is now available for: IMI2-2016-09-01(IMI2-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}